Supplemental Figure 2 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers
Year: 2023
Type: supplementary-materials
Abstract: In vivo orthotopic lung cancer model for the role of miR-155 in chemoresistance. (A) Injection and treatment schedule for CDDP (green arrows) and anti-miR negative control (NC) or anti-miR-155 liposomal nanoparticles (red stars) for four different treatment groups: mice that were injected with A549-LVEV cells and untreated (group 1), injected with A549-LVEV cells and treated with anti-miR-NC and CDDP (group 2), injected with A549-155LV cells and treated with anti-miR-NC and CDDP (group 3), and injected with A549-155LV cells and treated with anti-miR-155 and CDDP (group 4). (B) Representative pictures of dissected mice belonging to each of the treatment groups described in panel A of this Figure. Tumor nodules are marked by dotted white circles. (C-D) Graphs of the primary tumor size (C) and aggregate mass of nodules in mediastinum (D) of the four treatment groups mentioned above. (E) In situ hybridization for miR-155 for each of the four treatment groups mentioned above. (F) Immunohistochemical analysis for Ki-67 (proliferation) and CD31 (angiogenesis), as well as the TUNEL assay (apoptosis) and TP53 immunostaining for each of the four treatment groups mentioned above.
Authors: Katrien Van Roosbroeck, Francesca Fanini, Tetsuro Setoyama, Cristina Ivan, Cristian Rodriguez-Aguayo, Enrique Fuentes-Mattei, Lianchun Xiao, Ivan Vannini, Roxana S. Redis, Lucilla D'Abundo, Xinna Zhang, Milena S. Nicoloso, Simona Rossi, Vianey Gonzalez-Villasana, Rajesha Rupaimoole, Manuela Ferracin, Fortunato Morabito, Antonino Neri, Peter P. Ruvolo, Vivian R. Ruvolo, Chad V. Pecot, Dino Amadori, Lynne Abruzzo, Steliana Calin, Xuemei Wang, M. James You, Alessandra Ferrajoli, Robert Orlowski, William Plunkett, Tara M. Lichtenberg, Ramana V. Davuluri, Ioana Berindan-Neagoe, Massimo Negrini, Ignacio I. Wistuba, Hagop M. Kantarjian, Anil K. Sood, Gabriel Lopez-Berestein, Michael J. Keating, Muller Fabbri, George A. Calin
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361921080